MBio Diagnostics is now LightDeck Diagnostics!
LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise. The company’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. LightDeck is introducing a portfolio of in vitro diagnostic panels, the first is an on-the-spot test for COVID-19. The LightDeck platform is currently commercialized in veterinary diagnostics and for environmental testing. Learn more at www.LightDeckDx.com
Platform Technology
The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The LightDeck® platform was designed to meet customer requirements:
• Quality: Highly sensitive tests that deliver lab-quality results
• Quick: Actionable data in as little as 5 minutes with a simple procedure
• Quantitative: More data to inform treatment decisions
• Multiplex: Multiple related tests for better precision plus internal quality control to maximize safety
The test procedure is simple enough that an untrained user can perform testing almost anywhere. Panels can be configured to run multiple related tests simultaneously to help diagnosis or rule-out a specific condition. Internal quality control runs with every test to ensure quality and not report questionable results.
LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise. The company’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. LightDeck is introducing a portfolio of in vitro diagnostic panels, the first is an on-the-spot test for COVID-19. The LightDeck platform is currently commercialized in veterinary diagnostics and for environmental testing. Learn more at www.LightDeckDx.com
Platform Technology
The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The LightDeck® platform was designed to meet customer requirements:
• Quality: Highly sensitive tests that deliver lab-quality results
• Quick: Actionable data in as little as 5 minutes with a simple procedure
• Quantitative: More data to inform treatment decisions
• Multiplex: Multiple related tests for better precision plus internal quality control to maximize safety
The test procedure is simple enough that an untrained user can perform testing almost anywhere. Panels can be configured to run multiple related tests simultaneously to help diagnosis or rule-out a specific condition. Internal quality control runs with every test to ensure quality and not report questionable results.
Location: Colombia, Boyacá
Employees: 51-200
Total raised: $11M
Founded date: 2009
Investors 3
| Date | Name | Website |
| - | Entrada | entradaven... |
| - | Arizona Te... | arizonatec... |
| - | Arizona Te... | azti.membe... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.10.2020 | - | $11M | - |
Mentions in press and media 4
| Date | Title | Description |
| 08.07.2021 | LightDeck secures $35M federal contract to fund rapid COVID test | LightDeck Diagnostics, a Boulder-based diagnostic-testing company, has secured a $35.1 million contract from the U.S. Department of Defense to increase production capacity of its COVID-19 antibody test. The contract was awarded July 6, in c... |
| 04.02.2021 | LightDeck Diagnostics of Boulder raises $9.9M | LightDeck Diagnostics, a firm building equipment for rapid diagnosis of COVID-19 and other illnesses, has raised an additional $9.9 million. The Boulder company raised those funds by selling a combination of equity and future warrants, acco... |
| 30.10.2020 | LightDeck Diagnostics raises $11M for rapid COVID tests using laser technology | The company rebranded from MBio Diagnostics earlier this month One of the most disheartening aspects of the whole COVID-19 pandemic has been the lack of affordable and fast-acting testing. Tests are too expensive, too scarce, and they take ... |
| 29.10.2020 | LightDeck Diagnostics has $11 million for its new, high-speed way to test for COVID-19, sepsis and heart attack | LightDeck Diagnostics, a company formed earlier this year from the merger of startups mBio and Brava Diagnostics, has raised $11 million in funding for a new high-speed COVID-19 test, according to a statement. The company’s novel test uses ... |